Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

被引:3
|
作者
Suaiti, Lubna [1 ]
Sullivan, Travis B. [2 ]
Rieger-Christ, Kimberly M. [2 ]
Servais, Elliot L. [3 ]
Suzuki, Kei [4 ,6 ]
Burks, Eric J. [1 ,2 ,5 ]
机构
[1] Boston Univ, Boston Med Ctr, Dept Pathol & Lab Med, Sch Med, Boston, MA USA
[2] Lahey Hosp & Med Ctr, Dept Translat Res, Ian C Summerhayes Cell & Mol Biol Lab, Burlington, MA USA
[3] Lahey Hosp & Med Ctr, Dept Surg, Burlington, MA USA
[4] Boston Univ, Boston Med Ctr, Dept Surg, Sch Med, Boston, MA USA
[5] Boston Univ Mallory Pathol Associates, Dept Pathol & Labora tory Med, 670 Albany St,Suite 304, Boston, MA 02118 USA
[6] INOVA, Dept Surg, Div Thorac Surg, Falls Church, VA USA
关键词
Lymphovascular; AJCC; NCCN; Pathology; Adjuvant; LYMPHOVASCULAR INVASION; PROGNOSTIC IMPACT; VESSEL INVASION; MICROVASCULAR INVASION; LYMPHATIC INVASION; NUCLEAR-DIAMETER; PRIMARY TUMOR; BLOOD-VESSEL; CANCER; INDICATOR;
D O I
10.1016/j.cllc.2022.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NCCN-guidelines list vascular invasion (VI) as a risk-factor warranting consideration of adjuvant therapy among stage IB NSCLC. Among resected stage IA2-IB LUAD (n =344) and LUSC (n =102), VI predicted worse 5-year RFS for LUAD (64% vs. 90%, P <0.001) but not LUSC (83% vs. 80%, P =0.852). Guidelines should be modified to specify VI as a risk-factor only for stage I adenocarcinoma. Background: Lymphovascular invasion (LVI) is an adverse prognostic feature in resected stage I non-small cell lung cancer (NSCLC); however, it is unclear if the prognostic significance applies to both lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Materials and Methods: A retrospective review of H&E-stained slides from surgically resected AJCC 8th ed. stage IA2-IB LUAD (n = 344) and LUSC (n = 102) from two institutions was performed. LVI was defined as either lymphatic (LI) or vascular (VI) invasion. Outcomes were assessed by 5-year recurrence-free survival (RFS) estimates using the Kaplan-Meier method. Results: The cohorts of LUAD and LUSC showed no significant differences in 5-year RFS (81% each), stage, age, race, or surgical procedure. The presence of LVI, VI, and LI was predictive of 5-year RFS for LUAD (LVI + 71% vs. LVI -92%, P < 0.001; VI + 64% vs. VI -90%, P < 0.001; LI + 75% vs. LI -84%, P = 0.030) but not LUSC (LVI + 84% vs. LVI -79%, P = 0.740; VI + 83% vs. VI-80%, P = 0.852; LI + 84% vs. LI -81%, P = 0.757). Among LUAD with LVI, VI was a stronger predictor of 5-year RFS than the remaining subset of VI-LI + tumors (64% vs. 87%, P = 004). Subset analysis of LI among LUAD stratified by VI showed no significant prognostic advantage to adding LI for risk stratification (VI-LI + 87% vs. VI-LI -92%, P = 0.347 & VI + LI + 62% vs. VI + LI-66%, P = 0.422). VI was present in 36% of LUAD. Conclusion: Vascular invasion is a strong predictor of recurrence in stage IA2-IB LUAD but not in LUSC. Adjuvant therapy trials should be directed at this subgroup.
引用
收藏
页码:E126 / E133
页数:8
相关论文
共 50 条
  • [21] LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma
    Yu, Chengyong
    Hou, Liyan
    Cui, Hailing
    Zhang, Liyan
    Tan, Xiaodong
    Leng, Xuejiao
    Li, Yingbo
    FUTURE ONCOLOGY, 2018, 14 (24) : 2483 - 2492
  • [22] The Immune Microenvironment Predicts Recurrence in Early Stage Lung Adenocarcinoma
    Kammer, M. N.
    Mori, H.
    Vasiukov, G.
    Atwater, T.
    Chen, H.
    Borowsky, A.
    Massion, P. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [23] Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung
    Tsutani, Yasuhiro
    Murakami, Shuji
    Miyata, Yoshihiro
    Nakayama, Haruhiko
    Yoshimura, Masahiro
    Okada, Morihito
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 47 (06) : 1022 - 1026
  • [24] STAGE IA SQUAMOUS CELL CARCINOMA OF UTERINE CERVIX
    FOUSHEE, JHS
    GREISS, FC
    LOCK, FR
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1969, 105 (01) : 46 - &
  • [25] Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma
    Yang, Chi-Fu Jeffrey
    Wang, Hanghang
    Kumar, Arvind
    Wang, Xiaofei
    Hartwig, Matthew G.
    D'Amico, Thomas A.
    Berry, Mark F.
    CHEST, 2017, 152 (06) : 1239 - 1250
  • [26] PATHOLOGICAL VASCULAR INVASION AND THE HISTOLOGICAL GRADE OF DIFFERENTIATION PREDICT RECURRENCE IN RESECTED STAGE IA NON-SMALL CELL LUNG CANCER
    Shimada, Yoshihisa
    Saji, Hisashi
    Yoshida, Koichi
    Kakihana, Masatoshi
    Honda, Hidetoshi
    Nomura, Masaharu
    Usuda, Jitsuo
    Kajiwara, Naohiro
    Ohira, Tatsuo
    Ikeda, Norihiko
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S476 - S477
  • [27] NFIX downregulation independently predicts poor prognosis in lung adenocarcinoma, but not in squamous cell carcinoma
    Ge, Jun
    Dong, Hang
    Yang, Ye
    Liu, Bin
    Zheng, Min
    Cheng, Qing
    Peng, Li
    Li, Juan
    FUTURE ONCOLOGY, 2018, 14 (30) : 3135 - 3144
  • [28] Treatment options and prognosis of patients with lung squamous cell cancer in situ: a comparative study of lung adenocarcinoma in situ and stage IA lung squamous cell cancer
    Zhang, Kaixuan
    Chen, Hao
    Jiang, Yan
    Chen, Qiankun
    Su, Bo
    Zhou, Xiao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (06) : 1276 - +
  • [29] Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer
    Katagiri, Yu
    Jingu, Keiichi
    Yamamoto, Takaya
    Matsushita, Haruo
    Umezawa, Rei
    Ishikawa, Yojiro
    Takahashi, Noriyoshi
    Takeda, Kazuya
    Tasaka, Shun
    Kadoya, Noriyuki
    JAPANESE JOURNAL OF RADIOLOGY, 2021, 39 (06) : 611 - 617
  • [30] Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer
    Yu Katagiri
    Keiichi Jingu
    Takaya Yamamoto
    Haruo Matsushita
    Rei Umezawa
    Yojiro Ishikawa
    Noriyoshi Takahashi
    Kazuya Takeda
    Shun Tasaka
    Noriyuki Kadoya
    Japanese Journal of Radiology, 2021, 39 : 611 - 617